Total submissions: 10
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Genomic Research Center, |
RCV000785001 | SCV000923551 | uncertain significance | Ehlers-Danlos syndrome due to tenascin-X deficiency | 2019-01-01 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001662817 | SCV001874227 | uncertain significance | not provided | 2023-05-01 | criteria provided, single submitter | clinical testing | Has not been previously published as pathogenic or benign to our knowledge; In silico analysis supports that this missense variant has a deleterious effect on protein structure/function |
Genome Diagnostics Laboratory, |
RCV002279528 | SCV002566224 | likely benign | Ehlers-Danlos syndrome | 2021-04-05 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002424780 | SCV002730538 | likely benign | Cardiovascular phenotype | 2024-03-12 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Fulgent Genetics, |
RCV002493432 | SCV002803892 | uncertain significance | Ehlers-Danlos syndrome due to tenascin-X deficiency; Vesicoureteral reflux 8 | 2022-05-02 | criteria provided, single submitter | clinical testing | |
Ce |
RCV001662817 | SCV002821365 | likely benign | not provided | 2024-06-01 | criteria provided, single submitter | clinical testing | TNXB: BP4 |
Prevention |
RCV003928271 | SCV004746015 | likely benign | TNXB-related disorder | 2022-12-22 | criteria provided, single submitter | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |
Breakthrough Genomics, |
RCV001662817 | SCV005188883 | uncertain significance | not provided | criteria provided, single submitter | not provided | ||
Genome Diagnostics Laboratory, |
RCV001662817 | SCV001977737 | likely benign | not provided | no assertion criteria provided | clinical testing | ||
Genome Diagnostics Laboratory, |
RCV001662817 | SCV001978399 | likely benign | not provided | no assertion criteria provided | clinical testing |